Novocure (NVCR) revenue and earnings history
Novocure reported revenue of $605M for fiscal 2024 (year ended Dec 31, 2024), +18.8% on the year before, and net income of −$169M.
Over 11 years, from fiscal 2013 to fiscal 2024, revenue grew at a compound rate of +44.7% a year.
Revenue and net income, 12 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024ended Dec 31, 2024 | $605M+18.8% | −$170M | −$169M | −$26.4M | $42.9M | −$69.2M | $160M | — | — | $164M | $97.3M | 10-K |
| 2023ended Dec 31, 2023 |
The latest quarter, insider trades and fund moves: Novocure (NVCR) on OQRO.
Common questions
What was Novocure's revenue in fiscal 2024?
$605M for the year ended Dec 31, 2024, as reported in its 10-K filed Feb 26, 2026. That is +18.8% on fiscal 2023 ($509M).
How fast has Novocure's revenue grown?
From $10.4M in fiscal 2013 to $605M in fiscal 2024: a compound annual growth rate of +44.7% over 11 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Novocure tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
